Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | JAK2 V617F |
Gene Variant Detail | |
Relevant Treatment Approaches | JAK Inhibitor (Pan) JAK Inhibitor (Pan) - ATP competitive JAK2 Inhibitor JAK2 Inhibitor - ATP competitive |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04557956 | Phase Ib/II | Tazemetostat Dabrafenib + Tazemetostat + Trametinib | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment | Recruiting | USA | 0 |
NCT02689336 | Phase II | Erlotinib + Temozolomide | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | Withdrawn | 0 | |
NCT04644211 | Phase II | Ruxolitinib | Ruxolitinib in Thrombocythemia and Polycythemia Vera | Recruiting | USA | 0 |
NCT04116502 | Phase III | Ruxolitinib Hydroxyurea Alpha 2 Interferon | MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polcythemia Vera (MITHRIDATE) | Recruiting | 1 | |
NCT04537715 | Phase I | Itraconazole + Tazemetostat Rifampin + Tazemetostat | A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat | Active, not recruiting | USA | ESP | 0 |
NCT04517851 | Phase I | Elotuzumab | Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis | Recruiting | USA | 0 |
NCT03854474 | Phase Ib/II | Pembrolizumab + Tazemetostat | Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma | Recruiting | USA | CAN | 0 |